All lobbying filings

OGR

OGR filed a Q3 report for AMGEN USA INC on October 16, 2026, reporting $50,000 in lobbying income.

Lobbying for AMGEN USA INC

All filings by OGR · Everything AMGEN USA INC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 16, 2026

Income

$50,000

What the client paid this registrant for the period.

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare Part D and Medicare Part B reimbursement and coverage. Issues related to drug pricing. Issues related to biosimilar regulation. Issues related to 340B reform.

Taxation/Internal Revenue Code

Issues related to Puerto Rico.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.